IRA’s Orphan Drug Exemption Could Lead to More Off-Label Prescribing

Rare disease advocates also argue that the Medicare’s government drug price negotiation orphan drug exemption – which only applies when a drug has one orphan designation – will harm other government efforts aimed at more efficient drug development.

Zebras
Rare disease advocates believe IRA will jeopardize filing of supplemental marketing applications for orphan drugs. • Source: Shutterstock

The limited orphan drug exemption in the Inflation Reduction Act’s Medicare price negotiation program could shift more drug use, particularly for rare diseases, into the off-label space and make it more challenging to ensure insurance reimbursement for those products, rare disease advocates worry.

The US Centers for Medicare and Medicaid Services has said that the IRA allows only orphan drugs with one rare...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet